Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

stvyr™ is a novel smallpox antiviral agent being developed by SIGA for the treatment and prevention of morbidity and mortality associated with exposure to the causative agent of smallpox. SIGA filed an appeal of the final judgment, which was argued before the Delaware Supreme Court in January 2013. For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors
Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with our interest in Arestvyr™, the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... --  Sequenom, Inc. (NASDAQ: SQNM ), ... solutions, and Mayo Medical Laboratories (MML), the ... the United States , have announced a license ... "We have great appreciation for Mayo Clinic,s commitment ... the opportunity to partner with the organization,s leading clinical ...
(Date:7/29/2014)... CITY, Md. , July 29, 2014 /PRNewswire/ ... announced a new and updated program for the ... 10 – 12, 2014 in Amelia Island ... CROs, sites and investigators remains unchanged, however, the ... purposeful exchange and networking opportunity among all stakeholders ...
(Date:7/29/2014)... SANTA CLARA, Calif. , July 29, 2014 ... research services agreement with FORMA Therapeutics, Inc., to ... capabilities and proprietary fragment-based lead discovery platform for ... are really excited about the opportunity to work ... the fields of epigenetics and protein homeostasis. FORMA ...
(Date:7/29/2014)... 29, 2014 July 29, 2014 ... in the biotechnology industry, announced that it has ... Inc. to explore financing opportunities that build shareholder ... breakthrough vaccine platform with the potential to transform ... exclusively licensed the well-established LAMP platform from Johns ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3
... PRESENTS AT THOMAS WEISEL WEDNESDAY, SEPTEMBER 3RD AND NEWSMAKERS ... INDUSTRY CONFERENCE THURSDAY, SEPTEMBER 4TH, SAN DIEGO, Aug. ... today that Kevin Gorman, President and Chief,Executive Officer will ... Boston and the NewsMakers in the Biotech Industry Conference,in ...
... today announced it was named to Inc. magazine’s ... nationwide for a second consecutive year. The firm ... range of industries, helping companies operate more efficiently ... of the Chicago area’s top 100 businesses, growing ...
... ( www.chemlifecycle.com ) has finalized an agreement today with Chemical ... Management Systems (EMS) software for their new venture. , ... ... -- Chemical Lifecycle Management - a strategic alliance formed by ...
Cached Biology Technology:Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference 2 Integrated Project Management Named to "Inc. 5000" for Second Year : One of the Top 100 Fastest-Growing Companies in Chicago Area 2Chemical Lifecycle Management Chooses Chemical Safety's EMS Software 2
(Date:7/29/2014)... ground breaking new book that brings together two of ... raise the profile of insect fossils through stunning photographs ... Penney and James E Jepson, details the incredible preservation ... setting the scene for what these remarkable fossils can ... even the future of our planet. Like the mosquito ...
(Date:7/29/2014)... of cell, including sperm, bacteria and algae, propel ... protrusions, about one-hundredth of a millimetre long, function ... Similar, shorter structures called cilia are found on ... roles such as moving liquids over the cell. ... they transport mucus and expel pathogens from our ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2
... WI, JUNE 30, 2011 -- Agroforestry, the deliberate placement ... capture substantial amounts of carbon on agricultural lands while ... tools for accurately estimating current and projected carbon values ... an effective carbon-capturing option. Only occupying about 2 to ...
... scientific results from an ambitious voyage led by a group ... San Diego offer a stark view of human pollution and ... been labeled as the "Great Pacific Garbage Patch." Two ... or SEAPLEX, found evidence of plastic waste in more than ...
... HFES invites you to register to attend the 55th ... Red Rock Hotel in Las Vegas! Early bird discounts ... the Registration Information page at http://www.hfes.org/web/HFESMeetings/2011registration.html for ... more. Online registration is available at http://tinyurl.com/3drb8hz . ...
Cached Biology News:Scripps study finds plastic in 9 percent of 'garbage patch' fishes 2Scripps study finds plastic in 9 percent of 'garbage patch' fishes 3HFES 2011 registration is now open 2
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... ICE-family proteases/caspases initiates apoptosis in mammalian cells. ... Kit provides a simple and convenient means ... cytometry in intact cells. The assay ... residues linked to rhodamine 110 (D2R), a ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Biology Products: